Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chugai Licenses Novel Anticancer Agent FF284 to Debiopharm of Switzerland
January 10, 2013
- Pharmaceutical Firms’ Leaders Hopeful of New Products and Determined to Build Stronger Business Foundations
January 9, 2013
- AbbVie to Focus on Specialty Care, “Not Interested” in Established Markets: CEO Winer
January 9, 2013
- Sanofi Transfers Marketing Rights from Genzyme for Fludara
January 9, 2013
- Ajinomoto Pharmaceuticals Launches Atelec in Vietnam
January 9, 2013
- Novartis Pharma and Eisai Terminate Copromotion Agreement for COPD Therapies
January 9, 2013
- Bayer Yakuhin Files Eylea for Macular Edema Associated with CRVO
January 9, 2013
- Japan Should Invest More in Whole Genome Sequencing and Interpretation of Cancer-related Genomic Abnormalities: Dr Nakagawa of RIKEN
January 9, 2013
- BONAC Offers Solutions to Overcome Difficulties Faced in Development of Nucleic Acid Medicines: Managing Director Mizutani
January 9, 2013
- Nippon Kayaku Ups FY2012 Outlook for Pharma Biz, Anticancer Generics Brisk
January 8, 2013
- Abbott Japan’s Spin-Off AbbVie G.K. Starts Operations in January with CEO Winer
January 8, 2013
- “Appropriate Expressions” of Disease Awareness Ads Being Tested
January 7, 2013
- Sanofi K.K. Acquires DPP-4, SGLT-2 Inhibitors from Novartis, Chugai Aiming for Growth of Its Own Major Products for Diabetes through Synergism
January 7, 2013
- Lilly and BI in Long-term Collaboration; AZ and BMS Expanding Product Lineup
January 7, 2013
- Kowa Acquires 2 Major Products for “Post-Livalo” Era; How to Avoid Competition between Partners Holds Key in Comarketing
January 7, 2013
- Kyowa Kirin to Enhance Nephrology Lineup with DPP-4 Inhibitor; Companies Aiming to Capture Market through “2-Sword” Strategy
January 7, 2013
- Yoshindo, Ajinomoto Pharmaceuticals to Establish Joint Venture in Infusion and Dialysis Business
December 28, 2012
- Kissei Submits Application for Additional Indications for Combination Therapy of Glufast and DPP-4 Inhibitor or Biguanide
December 28, 2012
- Takeda Terminates Agreement with US Company on Anti-Obesity Drug Development
December 27, 2012
- Mitsubishi Chemical HD to Acquire Qualicaps
December 27, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…